Cargando…

Acute myopericarditis following administration of the BNT162b2 booster vaccine against COVID19

Detalles Bibliográficos
Autores principales:	Sivan, S.K., Francis, D.D., Ruhani, A.I., Abidin, S.K. Zainal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	General Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771585/ http://dx.doi.org/10.1016/j.ijcard.2022.10.116

Ejemplares similares

Myopericarditis After BNT162b2 mRNA Vaccination With Incidental Intramyocardial Bridging
por: Elghazal, Mohamed, et al.
Publicado: (2023)

Acute Myopericarditis After the Third Vaccination of BNT162b2 in a Middle-Aged Man
por: Nakawatase, Satoshi, et al.
Publicado: (2022)

Acute myocarditis after administration of BNT162b2 vaccine against COVID-19
por: Cueva-Recalde, Juan F., et al.
Publicado: (2023)

Acute Myocarditis Following the Administration of the Second BNT162b2 COVID-19 Vaccine Dose
por: Miqdad, Mohammed A, et al.
Publicado: (2021)

Still's Disease and Myopericarditis
por: Kumar, Manish, et al.
Publicado: (2019)

COVID-19 Vaccine-Induced Pneumonitis, Myositis and Myopericarditis
por: Farooq, Mariya, et al.
Publicado: (2022)

Acute Myopericarditis in the Post COVID-19 Recovery Phase
por: Rivera-Morales, Mark D, et al.
Publicado: (2020)

Acute Myopericarditis with Crohn's Disease Flare-up
por: Kumar, Manish, et al.
Publicado: (2019)

Myopericarditis as a Manifestation of Long COVID Syndrome
por: Vera-Lastra, Olga, et al.
Publicado: (2021)

Myopericarditis following both BNT162b2 and NVX-CoV2373
por: Ahmad, Saima, et al.
Publicado: (2022)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

The Myth of Colchicine in Treating Myopericarditis: Case Report and Literature Review
por: Al-Zakhari, Rana, et al.
Publicado: (2020)

Acute Myopericarditis in the Setting of Crohn’s Colitis: Challenging Management Decisions
por: Daloya, Jordan, et al.
Publicado: (2022)

Myopericarditis with hemorrhagic pericardial effusion following BNT162b2 mRNA COVID-19 vaccine()
por: Generette, Gabriela S., et al.
Publicado: (2022)

Pfizer BNT 162b2 COVID-19 vaccine–induced fulminant myopericarditis: A case study
por: Montarello, Natalie L., et al.
Publicado: (2023)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

COVID-19 Vaccine Cardiac Complications: A Case Series on Implications of Marijuana in Adolescents With Myopericarditis
por: Zaveri, Sahil, et al.
Publicado: (2022)

Myopericarditis Following the Third Dose of COVID-19 mRNA Vaccination: A Case Report
por: Saeed, Aamir, et al.
Publicado: (2023)

A Young Lady With Myopericarditis: An Unusual Presentation of COVID-19 Infection
por: Hasan, Md Nazmul, et al.
Publicado: (2022)

COVID-19 Myopericarditis With Pericardial Effusion Complicated With Cardiac Tamponade and Rhabdomyolysis
por: Abdelmottaleb, Wael, et al.
Publicado: (2022)

Myopericarditis Associated With Marijuana Intake: A Case Report and Literature Review
por: Rahman, Ali, et al.
Publicado: (2023)

Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
por: Nishizawa, Toshinori, et al.
Publicado: (2022)

Myopericarditis After mRNA COVID-19 Vaccine in a Patient With Recent History of COVID-19
por: Elhouderi, Eiman, et al.
Publicado: (2022)

A Case of Myopericarditis and Cardiac Tamponade as the Initial Presentation of COVID-19 Infection
por: Gioia, Michael A, et al.
Publicado: (2021)

COVID-19-Induced Myopericarditis Leading to Cardiac Tamponade: An Unusual Case Presentation
por: Shah, Niel, et al.
Publicado: (2022)

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

A Case of Isolated SARS-CoV-2 Fulminant Myopericarditis Without Respiratory Failure
por: Afriyie, Felix, et al.
Publicado: (2021)

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
por: Mofaz, Merav, et al.
Publicado: (2022)

Myopericarditis After COVID-19 Booster Dose Vaccination
por: Sharff, Katie A., et al.
Publicado: (2022)

Acute Myopericarditis After First Dose of mRNA-1273 SARS-CoV-2 Vaccine in a Young Adult
por: Fadah, Kahtan, et al.
Publicado: (2022)

Protection against Covid-19 by BNT162b2 Booster across Age Groups
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Serum C reactive protein predicts humoral response after BNT162b2 booster administration
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

Type I Spontaneous Coronary Artery Dissection in a 33-Year-Old Male With Clinically Suspected Myopericarditis
por: Nisson, Cullen, et al.
Publicado: (2023)

Tick-Borne Myopericarditis With Positive Anaplasma, Lyme, and Epstein Barr Virus (EBV) Serology: A Case Report
por: Arshad, Hassaan, et al.
Publicado: (2023)

Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
por: Yechezkel, Matan, et al.
Publicado: (2023)

Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
por: Li, Rui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lk82731np9jii0o10ndtpu726e